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Abstract
Background Electronic monitoring is recommended for ac-
curate measurement of medication adherence but a possible
limitation is that it may influence adherence.
Purpose To test the reactive effect of electronic monitoring in
a randomized controlled trial.
Methods A total of 226 adults with type 2 diabetes and
HbA1c ≥58 mmol/mol were randomized to receiving their
main oral glucose lowering medication in electronic con-
tainers or standard packaging. The primary outcomes were
self-reported adherence measured with the MARS (Medica-
tion Adherence Report Scale; range 5–25) and HbA1c at
8 weeks.
Results Non-significantly higher adherence and lower HbA1c
were observed in the electronic container group (differences in
means, adjusting for baseline value: MARS, 0.4 [95 %
CI −0.1 to 0.8, p=0.11]; HbA1c (mmol/mol), −1.02
[−2.73 to 0.71, p=0.25]).
Conclusions Electronic containers may lead to a small in-
crease in adherence but this potential limitation is
outweighed by their advantages. Our findings support elec-
tronic monitoring as the method of choice in research on
medication adherence. (Trial registration Current Con-
trolled Trials ISRCT N30522359)
Keywords Measurement reactivity . Medication adherence .
Electronicmonitoring . Diabetes
Background
Accurate measurement of adherence is a prerequisite for rig-
orous research on the patterns, determinants and conse-
quences of medication adherence. Several different methods
are used to measure adherence, including self-reports, pill
counts, pharmacy records, plasma drug levels and electronic
monitoring. Each of these methods has advantages and disad-
vantages [1, 2]. However, electronic monitoring (e.g., by
container caps that record the date and time of each opening)
is widely recommended as themethod of choice in research on
medication adherence [3, 4]. Assuming that there is a one-to-
one correspondence between opening the container cap
and ingesting the prescribed dose of tablets, electronic
monitoring can provide detailed, precise and objective
data on daily adherence over an extended period. In
research on medication adherence, electronic monitoring
is used to analyze dosing patterns [5], as the primary
behavioral outcome in trials of medication adherence
interventions [6] and as the gold standard comparator
for validating other measures of adherence [7].
S. Sutton :W. Hardeman : I. Kellar
Behavioural Science Group, Primary Care Unit, Department of
Public Health and Primary Care, Institute of Public Health,
University of Cambridge, Cambridge, UK
A.<L. Kinmonth : S. Boase : J. Graffy : S. Griffin
Primary Care Unit, Department of Public Health and Primary Care,
Institute of Public Health, University of Cambridge, Cambridge, UK
D. Hughes
Centre for Health Economics and Medicines Evaluation, Bangor
University, Bangor, UK
A. T. Prevost
Department of Primary Care and Public Health Sciences, King’s
College London, London, UK
A. Farmer
Department of Primary Health Care Sciences, University of Oxford,
Oxford, UK
S. Sutton (*)
Institute of Public Health, University of Cambridge, Forvie Site,
Robinson Way, Cambridge CB2 0SR, UK
e-mail: srs34@medschl.cam.ac.uk
ann. behav. med. (2014) 48:293–299
DOI 10.1007/s12160-014-9595-x
A possible limitation of electronic monitoring is that it may
influence adherence. Switching research participants to elec-
tronic medication containers may disrupt established routines
and lead to reduced adherence. On the other hand, participants
may increase adherence because they know that the re-
searchers will be able to tell how adherent they have been
and they wish to appear maximally adherent or because the
medication container acts as a novel visual prompt or cue.
There is increasing interest in the possible reactive effects
of measurement on behavior and other outcomes [8, 9].Where
they occur, reactive effects on behavior are usually positive,
i.e., where the behavior is desirable, measurement produces an
increase. Whether positive or negative, measurement effects
may threaten the validity of conclusions that are drawn from
research studies. For example, in an uncontrolled single-group
study designed to estimate the effect of an adherence inter-
vention, the use of electronic monitoring to assess adherence
may lead to a biased estimate of the intervention effect.
Denhaerynck and colleagues [10] identified six studies that
examined the possible effect of electronic monitoring on
medication adherence [11–16]. The findings were inconclu-
sive. Only two of the studies [15, 16] were randomized
controlled trials. Elixhauser et al. [15] tested the effect of
electronic blister packs compared with standard packaging
over a period of 2–4 months in a sample of 93 psychiatric
outpatients treated with lithium. Of four measures of medica-
tion adherence, only one showed a statistically significant
difference between groups: the mean percentage of prescrip-
tion refills obtained was 82 % in the electronically monitored
group versus 69 % in the control group (p<0.01). Wagner and
Ghosh-Dastidar [16] comparedmonitoring using an electronic
medication container with control in 120 HIV-positive pa-
tients on highly active antiretroviral therapy (HAART) over
a period of 4 weeks. The adherence measure was the mean
percentage of pills taken as prescribed based on a medication
recall interview covering the previous 3 days. Adherence was
high at baseline in both groups (electronic monitoring 93 %;
control 92 %) and remained high at follow up with no differ-
ence between groups (91 % vs. 94 %, p=0.73).
This paper reports a randomized controlled trial of the
effect on adherence of dispensing medication in an electronic
container that recorded the date and time of each opening
(TrackCap, Aardex, Zurich, Switzerland) compared with stan-
dard packaging over an 8-week period, in a sample of patients
with type 2 diabetes, using self-reported adherence as the
primary behavioral outcome and HbA1c, a summary measure
of recent glycemic (blood sugar) control, as the primary
clinical outcome. As well as reporting the trial analysis,
we examined the electronic monitoring data from the
group allocated to using electronic containers to look
for a pattern of daily adherence over the 8-week period
that might indicate an effect of electronic monitoring.
For example, a reduction in daily adherence over time
would be consistent with a short-lived positive effect of
electronic monitoring on adherence.
Methods
Participants
Patients were recruited from 13 primary care clinics in Ox-
fordshire, Buckinghamshire, Suffolk, Essex and Huntingdon-
shire (UK). Patients were eligible for inclusion if aged 18 years
or over with type 2 diabetes of at least 3 months’ duration, able
to give informed consent, currently taking any oral glucose-
lowering agent and with a HbA1c≥7.5 % (58 mmol/mol). (An
HbA1c level of 7.5 % or above is widely used in clinical
practice to indicate suboptimal blood glucose control which
may in turn reflect inadequate adherence to glucose-lowering
medication.) Those approached were deemed by their general
practitioner to be appropriate for tight glycemic control and
independent in medication taking.
Design
We used a parallel group trial design with 1:1 randomization
to electronic container or standard packaging and follow up at
8 weeks (Fig. 1). Randomization was conducted before the
baseline visit to the clinic (visit 1). Prior to visit 2 at 8 weeks, a
second randomization was conducted to evaluate the effect of
an adherence intervention delivered during that visit. The
adherence intervention trial is reported elsewhere [17];
the present study focuses on the 8-week period up to
and including visit 2.
Randomization of patients was carried out by the trial
statistician independently of the trial co-ordination and clinic
teams. A partial minimization procedure was used to dynam-
ically adjust randomization probabilities to balance the base-
line stratification variables (clinic, duration of diabetes, HbA1c
result from the clinic record and self-reported adherence).
After the participant had been allocated to group, both the
participant and the clinic nurse who saw the participant be-
came unblinded to the participant’s group allocation. Howev-
er, the laboratory staff who measured HbA1c were blind to
allocation. The London multi-centre research ethics commit-
tee reviewed and approved the protocol (06/MRE02/3).
Measures
The primary behavioral outcomewas self-reported medication
adherence measured by postal questionnaire sent 1 week be-
fore visit 2 (8 weeks) using the Medication Adherence Report
Scale (MARS) developed by Horne and colleagues [18]. We
used a five-item version of the MARS that asked about “using
your diabetes medicines in the last month”, with item
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responses scored on a 5-point scale from “always true” [1] to
“never true” [5]. Scores are summed to give a score ranging
from 5 to 25 with a higher score indicating higher self-
reported adherence (Table 1). In a pilot study, we found that
this version of the MARS had slightly better psychometric
properties than alternative versions (e.g., a version that did not
specify a time frame) and compared with the similar question-
naire developed by Morisky and colleagues [19]. In the pres-
ent study, MARS at follow up correlated significantly (r=
0.27; p=0.02; n=81) with electronically measured adherence
(using only the data from the last 30 days of the 8-week
follow-up period, to match the time frame of the self-report
measure). Cronbach’s alpha was 0.82 at baseline and
0.67 at follow-up. The primary clinical outcome was
HbA1c at 8 weeks.
A secondary behavioral outcome measure, available only
for participants in the group allocated to using electronic
containers, was whether or not the correct number of doses
of the main glucose lowering medication was taken as pre-
scribed on each day over the 8-week follow-up period as
measured by electronic monitoring.
Procedure
The clinic nurse identified eligible patients registered with the
clinic. Eligible patients were sent a letter from the clinic giving
Fig. 1 Flow of participants
through trial
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details of the trial, and a questionnaire asking about basic
demographics, medication regimen, medication adherence
(including the MARS) and beliefs about taking diabetes med-
icines. Responders were telephoned by the clinic nurse to
arrange a recruitment visit at the clinic (visit 1). In advance
of the visit, patients eligible and willing to take part were
allocated to be dispensed medication in the electronic
medication-monitoring device (TrackCap, Aardex, Zurich,
Switzerland) or in standard packaging. At the visit, informed
consent was obtained, clinical data were collected, blood was
taken, and questionnaires completed. For those patients allo-
cated to the electronic container, the nurse briefly explained its
purpose and use and gave them an information sheet
explaining how to use it. The patient was told that the con-
tainer counts the number of times that the lid is removed, that
they should only open and close the container at the time a
tablet is to be taken, and that they should only remove the
amount of medication required at the time. The nurse then
referred them to the clinic dispenser or pharmacist to dispense
their usual prescription for metformin or alternative oral glu-
cose lowering agent in the device. Other medication was
dispensed as usual, in standard packaging. For those allocated
to the other trial arm, the clinic dispenser or pharmacist
dispensed their medication as usual, in standard packaging.
Patients in both trial arms who used a pillbox to organize their
medications were able to continue to use this method during
the trial, with the proviso that those in the electronic
container arm had to use the electronic containers for
their main oral glucose lowering agent. A second visit
was arranged in 8 weeks.
In advance of the 8-week visit (visit 2), patients were sent a
questionnaire (which included the MARS) from the coordi-
nating center and were centrally randomized to the adherence
intervention or a standard care visit. The patients were not told
their intervention group allocation before they attended the
visit. At the beginning of the visit, patients in both groups had
blood samples taken for measurement of HbA1c.
Analysis
The adherence intervention trial was planned to follow up 200
patients [20]. For the measurement effect trial, this sample size
gave 80 % power to detect a difference of one point in the
MARS self-reported adherence measure assuming a standard
deviation of 2.5 (a small to medium effect size), and 80 %
power to detect a 0.5 % difference in HbA1c assuming a
Table 1 The Medication Adherence Report Scale (MARS) [14]
Many people find a way of using their medicines or tablets which suit
them. This may differ from the instructions on the label or what their
doctor has said. We would like to ask you a few questions about how
you take your diabetes medicines (tablets).
The following statements show some ways in which other people have
said they use their medicines.
For each of the statements below, please circle the number that best
describes how you have taken your diabetes medicines in the last
month.
1 I forget to take my diabetes medicines.
2 I alter the dose of my diabetes medicines.
3 I stop taking my diabetes medicines for a while.
4 I decide to miss out a dose of my diabetes medicines.
5 I take less of my diabetes medicines than instructed.
Table 2 Baseline characteristics of trial participants
Electronic container (n=111) Standard packaging (n=115) All participants (n=226)
% Male (n) 62.2 % (69) 67.8 % (78) 65.0 %(147)
Age (years) 63.7 (11.2) 62.8 (10.6) 63.2 (10.9)
IMD deprivation score (0–100)a,d 10.6 (6.3) 10.0 (6.8) 10.3 (6.6)
Duration of diabetes (years) 6.5 (4.8) 7.1 (5.4) 6.8 (5.1)
Weight (kg)e 94.5 (20.2) 97.8 (21.5) 96.2 (20.9)
% Treated with Metformin (n)f 70.0 (70) 77.3 (85) 73.8 (155)
Metformin daily dose (mg)b,g 1,767 (609) 1,695 (601) 1,728 (604)
Total number of medications taken/daye 5.6 (2.6) 6.0 (2.3) 5.8 (2.5)
Self-reported adherence (MARS,c range 5–25)h 23.8 (1.8) 23.4 (3.0) 23.6 (2.5)
HbA1c (%)
i 8.31 (1.28) 8.35 (1.20) 8.33 (1.24)
HbA1c (mmol/mol)
i 67.33 (13.99) 67.77 (13.12) 67.55 (13.55)
Values are mean (SD) unless otherwise stated
a Index of Multiple Deprivation
b For those treated with Metformin
cMedication Adherence Report Scale
Number of missing values: d 2, e 15, f 16, g 72, h 25, i 32
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standard deviation of 1.25 % (two-sided tests, 5 % signifi-
cance level).
Analysis of the trial data was by intention to treat. Out-
comes were analyzed using analysis of covariance adjusting
for their corresponding baseline value to improve precision.
The missing indicator method [21] was used so that patients
with a missing baseline value could be included. Since the
MARS score was skewed, the results were checked using a
Mann–Whitney U test.
An exploratory subgroup analysis was conducted to exam-
ine whether the effect of using the electronic container was
different among participants who used a pillbox to organize
their medications compared with the rest of the sample. This
was done by extending the analysis of covariance to incorpo-
rate a test for interaction between trial arm and pillbox use
(yes/no). An additional analysis (suggested by one of the
reviewers) was conducted to examine whether the effect of
using the electronic container was different among partici-
pants who were less adherent at baseline (as measured by
self-report) compared with those who were more adherent;
this involved testing the interaction between trial arm and
baseline adherence (treated as continuous).
Generalized estimating equations (GEE), which take ac-
count of the dependence of the observations within
individuals, were used to analyze change over time in the
proportion of participants in the electronic container group
who were adherent according to the electronic monitoring
data on each day over the 8-week follow-up period. The
analysis specified an autoregressive (order 1) correlation ma-
trix and robust standard errors and tested linear and quadratic
effects of time. Analyses were conducted in Stata 11 and
PASW 16.
Results
In the 13 participating clinics, 797 registered patients with
type 2 diabetes potentially meeting the inclusion criteria were
identified, of whom 273 responded as eligible and 226 were
randomized (Fig. 1). The two groups were similar at baseline
(Table 2). On average, participants were in their early 60s, had
had diabetes for less than 10 years, were taking six medica-
tions daily and reported high medication adherence (scored 24
out of 25 on the MARS).
Primary outcome data were available for 81 % and 85 % of
those randomized for MARS and HbA1c, respectively. Miss-
ing outcome data were due to failure to return the question-
naire for MARS and non-attendance at visit 2 for HbA1c. In
the main trial analysis, both outcomes showed a difference
between groups, with higher adherence and lower HbA1c in
the electronic container group, but the differences were not
statistically significant (p=0.11 and p=0.25, respectively; Ta-
ble 3). This was confirmed by the results of the non-
parametric test. There was no evidence that the effect of using
an electronic container was different among the 23 % of
participants who used a pillbox to organize their medications;
the tests for interaction between trial arm and pillbox use were
not statistically significant for self-reported adherence (p=
0.11) or HbA1c (p=0.71). There was also no evidence for an
interaction between trial arm and baseline adherence on ad-
herence at outcome (p=0.93).
Within the electronic container arm, Fig. 2 appears to show
a small reduction in the proportion adherent over time as
Table 3 Outcomes 8 weeks after randomization to electronic container or standard packaging
Electronic container Standard packaging Estimated effecta
(95 % CI)
p value
Baseline 8 weeks Baseline 8 weeks
Self-reported adherenceb 23.8 (1.8)c 24.2 (1.1)d 23.6 (2.5)e 23.8 (1.9)f 0.4 (−0.1 to 0.8)g 0.11
HbA1c (%)
HbA1c (mmol/mol)
8.31 (1.28)h
67.33 (13.99)h
8.22 (1.30)i
66.34 (14.21)i
8.36 (1.21)j
67.87 (13.23)j
8.39 (1.16)j
68.20 (12.68)j
−0.09 (−0.25 to 0.07)k
−1.02 (−2.73 to 0.71)k
0.25
Values are Mean (SD) unless otherwise stated
aAdjusted for baseline value
bMedication Adherence Report Scale (MARS)
Number of missing values: c 36, d 25, e 24, f 17, g 42, h 21, i 20, j 13, k 33
Fig. 2 Proportion of participants in the electronic container arm taking
their main oral glucose-lowering medication as prescribed on each day of
monitoring
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measured by electronic monitoring. However, neither linear
(p=0.09) nor quadratic (p=0.08) effects of time were statisti-
cally significant in the GEE analysis.
Discussion
The trial analysis showed no statistically significant difference
between electronic medication container and standard pack-
aging on either outcome measure at 8 weeks. The confidence
intervals around the estimates of the effect suggest that using
an electronic container did not reduce adherence but may have
increased it slightly.
A null effect may mask a negative effect in one subgroup
offset by a positive effect in another subgroup. We explored
the possibility that the effect differed in those participants who
used a pillbox to organize their tablets and whose medication-
taking routine may have been disrupted by switching to an
electronic container for their main glucose lowering agent, but
found no evidence for this.
The data from the electronic container group appeared to
show a small initial increase in adherence that reduced grad-
ually over time, which could be interpreted as being consistent
with the trial results. However, there was no significant effect
of time. This differed from the pattern observed in a study of
HIV patients which suggested that adherence reduced over
time and stabilized after 40 days [22].
Limitations of the present study concern the outcome mea-
sures and the high level of adherence at baseline, as reported in
a previous trial [16]. HbA1c is affected by a number of factors
in addition to adherence to hypoglycemic medication, and
8 weeks may not be a sufficiently long period to observe a
change in HbA1c arising from a change in adherence. The
MARS self-report measure referred to “diabetes medicines in
the last month”, so this would not have detected an initial short-
term increase or decrease in adherence. The MARS score
correlated significantly (r=0.27) with electronically measured
adherence, providing some evidence of validity, but this was
lower than the correlation of 0.42 reported for a ten-item
version of the scale in a sample of asthmatic adults [23].
For the purposes of both the adherence intervention study
and the measurement effect substudy reported here, we aimed
to recruit a sample of patients with type 2 diabetes who
showed suboptimal blood glucose control. The findings of
the intervention trial [17] showed that it was possible to
increase adherence in this group, though this was with adher-
ence measured by electronic monitoring not by self-report.
However, self-reported adherence was high at baseline in the
present study and this may have reduced the chances of
detecting an increase in adherence (though not of detecting a
reduction in adherence).
Further investigation of this possible ceiling effect revealed
that only 39 % of participants had the maximum score of 25 on
the MARS at baseline, and that it was theoretically possible for
the present study to have shown a statistically significant pos-
itive effect on self-reported adherence. An additional explorato-
ry analysis showed that there was no evidence that the effect of
using an electronic container was different in patients who were
less adherent at baseline (as measured by self-report) compared
with those who were more adherent. Nevertheless, future stud-
ies should aim to recruit less adherent patients.
Strengths of the present study include the trial design, with
central randomization, concealment of group allocation, base-
line comparability of groups and an acceptable proportion
(>0.8) of those randomized providing primary outcome data.
Unlike other measures of adherence, electronic monitoring
can provide detailed, precise and objective data on daily
adherence over an extended period. The findings of this trial
suggest that electronic containers may lead to a small increase
in adherence but this potential limitation is outweighed by
their advantages. Although other problems have been identi-
fied [10] and need further investigation, our findings support
electronic monitoring as the method of choice in research on
medication adherence.
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